An immunogenic cell death-related signature for prediction of prognosis and response to immunotherapy in breast cancer

作     者：Cong Li Fengzhu Guo Jingtong Zhai Xiaohan Liu Zhijun Li Binghe Xu 

作者机构：Department of Medical OncologyNational Cancer CenterNational Clinical Research Center for CancerCancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021China Department of Medical OncologySun Yat-sen University Cancer CenterGuangzhouGuangdong 510060China Department of Medical OncologyBeijing HospitalNational Center of GerontologyInstitute of Geriatric MedicineChinese Academy of Medical SciencesBeijing 100730China Department of Histology and EmbryologyBasic Medical CollegeChina Medical UniversityShenyangLiaoning 110122China 

出 版 物：《Chinese Medical Journal》 (中华医学杂志（英文版）)

年 卷 期：2024年第137卷第4期

页      面：487-489页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：breast immunotherapy chemotherapy 

摘      要：To the Editor:Tumor immune microenvironment plays a key role in breast cancer development and progression,which determines the long-term survival of breast cancer *** data have revealed that the application of cancer immunotherapy has some limitations,including generating weak immune responses due to inadequate delivery of immunostimulants to the immune cells.^([1])Thus,current clinical efforts are primarily focused on developing immune-based chemotherapy that can convert non-responders to responders.^([2])Immunogenic cell death(ICD)is a form of regulated cell death that is sufficient to activate an adaptive immune response.